165 related articles for article (PubMed ID: 31410509)
1. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.
Vornicova O; Haim N; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Oct; 84(4):919-923. PubMed ID: 31410509
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
3. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD
Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
[TBL] [Abstract][Full Text] [Related]
6. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
8. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
[TBL] [Abstract][Full Text] [Related]
9. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
11. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
[TBL] [Abstract][Full Text] [Related]
14. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
van Oosterom AT; Mouridsen HT; Nielsen OS; Dombernowsky P; Krzemieniecki K; Judson I; Svancarova L; Spooner D; Hermans C; Van Glabbeke M; Verweij J;
Eur J Cancer; 2002 Dec; 38(18):2397-406. PubMed ID: 12460784
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
16. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
[TBL] [Abstract][Full Text] [Related]
17. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
[TBL] [Abstract][Full Text] [Related]
18. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
